<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3871">
  <stage>Registered</stage>
  <submitdate>25/02/2013</submitdate>
  <approvaldate>25/02/2013</approvaldate>
  <nctid>NCT01799993</nctid>
  <trial_identification>
    <studytitle>Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia</studytitle>
    <scientifictitle>A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia</scientifictitle>
    <utrn />
    <trialacronym>INHALE 1</trialacronym>
    <secondaryid>2008-000906-35</secondaryid>
    <secondaryid>13084</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pneumonia, Bacterial</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Amikacin Inhalation Solution (BAY41-6551)
Treatment: drugs - Aerosolized Placebo

Experimental: Amikacin Inhalation Solution - Amikacin Inhalation Solution (BAY41-6551) for Inhalation and Pulmonary Drug Delivery System (PDDS Clinical)

Placebo Comparator: Aerosolized Placebo - Aerosolized placebo


Treatment: drugs: Amikacin Inhalation Solution (BAY41-6551)
400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)

Treatment: drugs: Aerosolized Placebo
Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients deemed to be clinical successes in the BAY41-6551 treatment group divided by the proportion of cured patients in the placebo treatment group.</outcome>
      <timepoint>Late follow-up (LFU) visit (day 28-32)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pneumonia-related mortality through the LFU visit</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Early Clinical Response which is based on CPIS scores, the presence of empyema or lung abscess, and all-cause mortality - Early Clinical Response success occurs if there is no rise of 2 points or more on Day 3, and a drop of 1 or more points on Day 5 and a drop 2 or more points on Day 10, and the absence of lung abscess or empyema by Day 10, and alive on Day 10.</outcome>
      <timepoint>Assessed through day 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of days on mechanical ventilation through the LFU visit</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of days in the ICU through the LFU visit</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients who received at least one dose of study drug and reported an adverse event</outcome>
      <timepoint>35-39 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients who received at least one dose of study drug and reported a serious adverse event</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression and incidence rates of organ failure</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality rate</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Identification of laboratory data outside normal ranges</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Per pathogen microbiological response rates at the Test-of-Cure (TOC) visit</outcome>
      <timepoint>17-19 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Per patient microbiological response rates at the TOC visit</outcome>
      <timepoint>17-19 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Microbiological recurrence rates at the TOC and LFU visits</outcome>
      <timepoint>17-19 days and 28-32 days respectively after start of treatment with study medication</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Emergence of new respiratory pathogens during the aerosol treatment period</outcome>
      <timepoint>Days 1-10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Emergence of resistance among baseline pathogens in those patients with persistent infection or colonization</outcome>
      <timepoint>28-32 days after start of treatment with study medication</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and non-pregnant, non-lactating females, 18 years of age or older

          -  Intubated and mechanically-ventilated

          -  Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on
             chest radiograph

          -  Presence of Gram-negative organism(s) by either Gram stain or culture of respiratory
             secretions, or suspected Gram-negative pathogen

          -  Impaired oxygenation

          -  Clinical Pulmonary Infection Score (CPIS) of at least 6

          -  Presence of or at least two risk factors for multi-drug resistant organisms</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of hypersensitivity to amikacin or other aminoglycosides

          -  Has received antibiotic therapy for Gram-negative pneumonia for greater than 48 hours
             at the time of randomization

          -  Known or suspected bacteremia secondary to Staphylococcus aureus

          -  A positive urine and/or serum beta-human Chorionic Gonadotropin pregnancy test

          -  Patients with a serum creatinine &gt; 2 mg/dL (177 Âµmol/L) [Exception: Patients with a
             serum creatinine &gt; 2 mg/dL (177 umol/L) and being treated with continuous renal
             replacement therapy (Continuous Veno-Venous Hemodialysis and CVVHemoDiafiltration) or
             daily hemodialysis will receive the aerosol study drug treatment]

          -  Has been on mechanical ventilation for &gt; 28 days

          -  Is participating in or has participated in other investigational interventional
             studies within the last 28 days prior to study treatment

          -  The risk of rapidly fatal illness and death within 72 hrs, or any concomitant
             condition not related to ventilator-associated pneumonia that, in the opinion of the
             investigator, precludes completion of study evaluations and the course of therapy

          -  Has an Acute Physiology and Chronic Health Evaluation (APACHE) II score &lt; 10

          -  Patients receiving veno-venous extracorporeal circulation membrane oxygenation (V-V
             ECMO)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>13/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>264</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>6/04/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,TAS,VIC</recruitmentstate>
    <hospital> - Blacktown</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Hobart</hospital>
    <hospital> - Clayton</hospital>
    <hospital> - Footscray</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Richmond</hospital>
    <hospital> - Wollongong</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>5011 - Adelaide</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3122 - Richmond</postcode>
    <postcode>2500 - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Auton. de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>CÃ³rdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires [Capital Federal]</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mendoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Parana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>AtlÃ¡ntico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Distrito Capital de BogotÃ¡</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Valle del Cauca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>BogotÃ¡</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 6</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Zlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gang''weondo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Nuevo Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Sonora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>San Luis PotosÃ­</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Toluca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaoshiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Trabzon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Nektar Therapeutics</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg
      (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System
      (PDDS) Clinical every 12 hours is safe and more effective than placebo (aerosolized normal
      saline) administered as an aerosol by the PDDS Clinical every 12 hours, in intubated and
      mechanically-ventilated patients with Gram-negative Pneumonia. The secondary endpoint
      objectives are to evaluate the superiority of aerosolized BAY 41-6551 versus aerosolized
      placebo in pneumonia-related mortality, the Early Clinical Response at Day 10, the days on
      ventilation, and the days in the intensive care unit (ICU).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01799993</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>